

# THE JOURNAL OF DERMATOLOGY

## INSTRUCTIONS FOR AUTHORS

### Latest information

- ✓ From April 1, 2013, the publication charge will change to
- ✓ ¥20,000 / US\$200 per printed page.
- ✓ Concise Communication: New category is added.
- ✓ Word limit of Letter to the Editor is changed to 500 words.
- ✓ New Conflict of Interest notification form is added.

### AIMS AND SCOPE

*The Journal of Dermatology* is the official English language journal of the Japanese Dermatological Association and the Asian Dermatological Association, and publishes original articles of a clinical or research nature. Papers in any field of dermatology will be considered.

### EDITORIAL REVIEW AND ACCEPTANCE

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed by two anonymous reviewers and the Editor. Final acceptance or rejection rests with the Editorial Board, who reserves the right to refuse any material for publication.

Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. They should be written in a clear, concise, direct style. Where contributions are judged as acceptable for publication on the basis of content, the Editor and the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

### SUBMISSION OF MANUSCRIPTS

Manuscripts should be submitted online at <http://mc.manuscriptcentral.com/jde>.

Authors must supply an email address as all correspondence will be by email. Two files should be supplied: the covering letter and the manuscript (in Word or rich text format (.rtf)). The covering letter should be uploaded as a file not for review. All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication.

- Submissions should be double-spaced.
- All margins should be at least 30 mm.
- All pages should be numbered consecutively in the top
- right-hand corner, beginning with the title page.

- Do not use Enter at the end of lines within a paragraph.
- Turn the hyphenation option off; include only those hyphens that are essential to the meaning.
- Specify any special characters used to represent non-keyboard characters. (Greek beta).
- Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German esszett) for  $\beta$
- Use a tab, not spaces, to separate data points in tables. If you use a table editor function, ensure that each data point is contained within a unique cell (i.e. do not use carriage returns within cells).

Each figure should be supplied as a separate file, with the figure number incorporated in the file name. Multi-panel figures (figures with parts a, b, c, d, etc.) should be submitted as a single file that contains all parts of the figure. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .eps or .tif files should be uploaded. Digital images supplied as low-resolution print-outs, PowerPoint files or PDFs cannot be used. Further instructions are available at the submission site.

For Assistance, please contact to the Editorial office of *The Journal of Dermatology* at the address below:

Japanese Dermatological Association,  
*The Journal of Dermatology* Editorial Office  
1-4 Hongo-4-chome, Bunkyo-ku Tokyo  
113-0033 Japan  
Email: [gakkai@dermatol.or.jp](mailto:gakkai@dermatol.or.jp)  
Tel: +81 3 3811 5099; Fax: +81 3 3812 6790.

### Covering letter

Papers are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. This must be stated in the covering letter.

The covering letter must also contain an acknowledgment that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified. If tables or figures have been reproduced from another source, a letter from the copyright holder (usually the Publisher), stating authorization to reproduce the material, must be attached to the covering letter.

### Conflict of Interest

Authors should declare any financial support or relationship that may pose conflict of interest as a Conflict of Interest Statement in the Conflict of Interest section of your manuscript and confirm that the results of this manuscript have not been distorted by research funding or conflicts of interest.

To download Conflict of Interest form, please visit [http://mc.manuscriptcentral.com/societyimages/jde/The\\_Journal\\_of\\_Dermatology\\_COI.pdf](http://mc.manuscriptcentral.com/societyimages/jde/The_Journal_of_Dermatology_COI.pdf). Such information will be held in confidence while the paper is under review and will not influence the editorial decision but, if the article is accepted for publication, the Editor will usually discuss with the authors the manner in which such information is to be communicated to the reader. Completion and inclusion of this Form is obligatory with the submission of all categories of article. If the form is not included or complete, the manuscript will not be considered for peer review.

### Author material archive policy

Authors who require the return of any submitted material that is accepted for publication should inform the Editorial Office after acceptance. If no indication is given that author material should be returned, the Publisher will dispose of all hardcopy and electronic material two months after publication.

### ETHICAL CONSIDERATIONS

Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004), available at <http://www.wma.net/en/10home/index.html>. *The Journal of Dermatology* retains the right to reject any manuscript on the basis of unethical conduct of either human or animal studies.

All investigations on human subjects must include a statement that the subject gave informed consent. Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used).

Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research.

### COPYRIGHT

Accepted papers will be passed to Wiley's production team for publication. The author

Updated January 2015

identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley's Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. FAQs about the terms and conditions of the standard copyright transfer agreements (CTA) in place for the journal, including terms regarding archiving of the accepted version of the paper, are available at: [http://authorservices.wiley.com/bauthor/faqs\\_copyright.asp](http://authorservices.wiley.com/bauthor/faqs_copyright.asp).

#### OnlineOpen – Wiley's Open Access Option

OnlineOpen is available to authors of articles who wish to make their article freely available to all on Wiley Online Library under a Creative Commons licence. In addition, authors of OnlineOpen articles are permitted to post the final, published PDF of their article on a website, institutional repository or other free public server, immediately on publication. With OnlineOpen the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made open access, known as 'gold road' open access.

#### OnlineOpen licenses

Authors choosing OnlineOpen retain copyright in their article and have a choice of publishing under the following Creative Commons License terms: Creative Commons Attribution License (CC BY); Creative Commons Attribution Non-Commercial License (CC BY NC); Creative Commons Attribution Non-Commercial-NoDerivs License (CC BY NC ND)

For more information about the OnlineOpen license terms and conditions, please go to [http://onlinelibrary.wiley.com/journal/10.1002/\(ISSN\)1467-8438/homepage/](http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1467-8438/homepage/).

#### Funder Open Access and self-archiving compliance

Please go to <http://olabout.wiley.com/WileyCDA/Section/id-406074.html> for more information on Wiley's compliance with specific Funder Open Access and Self Archiving Policies, and <http://olabout.wiley.com/WileyCDA/Section/id-820227.html> for more detailed information specially about Self-Archiving definitions and policies.

#### STYLE OF THE MANUSCRIPT

Manuscripts should follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors' revised 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication', as presented at <http://www.ICMJE.org>.

#### Spelling

The Journal uses US spelling and authors should therefore follow the latest edition of the *Merriam-Webster's Collegiate Dictionary*.

#### Units

All measurements must be given in SI or SI-derived units. Please go to the Bureau International des Poids et Mesures (BIPM) website at <http://www.bipm.fr> for more information about SI units.

#### Abbreviations

Abbreviations should be used sparingly - only where they ease the reader's task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

#### Trade names

Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

#### Scientific names

Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. However, for well-known species, the scientific name may be omitted from the article title. If no common name exists in English, the scientific name should be used only.

#### PARTS OF THE MANUSCRIPT

The length of manuscripts must adhere to the specifications under the section Manuscript Categories.

Manuscripts should be presented in the following order: (i) title page, (ii) abstract and key words, (iii) text, (iv) acknowledgments, (v) conflict of interest, (vi) references, (vii) supporting information, (viii) figure legends, (ix) tables (each table complete with title and footnotes) and (x) figures.

#### ORIGINAL ARTICLES

**Word limit:** 6,000 words including abstract.

**Abstract:** Unstructured

**Figures/Tables:** No limit

**References:** No limit.

**Description:** Arrange text as follows: (i) title page, (ii) abstract and key words, (iii) text, (iv) acknowledgments, (v) conflict of interest, (vi) references, (vii) supporting information, (viii) figure legends, (ix) tables (each table complete with title and footnotes) and (x) figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

#### CONCISE COMMUNICATION

**Word limit:** 1,500 words including abstract

**Abstract:** Unstructured

**Figures/Tables:** Up to 3

**References:** Up to 15.

**Description:**

a) A case report with mini review or with new observations of diseases, clinical findings or novel treatment outcomes.

b) Brief research paper.

Arrange text as follows: (i) title page, (ii) abstract and key words, (iii) text, (iv) acknowledgments, (v) conflict of interest, (vi) references, (vii) supporting information, (viii) figure legends, (ix) tables (each table complete with title and footnotes) and (x) figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

#### LETTERS TO THE EDITOR

**Word limit:** 500 words

**Authors:** Maximum ten authors.

**Abstract:** No abstract.

**References:** Up to 5.

**Figures/ tables:** Up to 1 (Multi panel figures allowed).

**Description:** The Letters to the editor department has three sections.

- **Notes & Comments:** Letters may be submitted to the Editor on any topic of discussion; clinical observations as well as letters commenting on papers published in recent issues.

- **Research Letters:** New or preliminary research findings may be considered for publication

- **Case Letters:** Conclusions based on uncontrolled trials and/or limited experience should be stated in appropriately tentative terms. Concise descriptions detailing one or two patients, early reports of therapeutic trials in one or several patients, and early reports of new drug reactions.

Letters to the editor of one printed pages or less will be published as soon as possible.

#### REVIEW ARTICLE

**Word limit:** 5,000 words.

**Abstract:** Unstructured.

**References:** No limit.

**Figures/tables:** No limit. (Minimum 1 image or figure)

**Description:** Reviews are comprehensive analyses of specific topics. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

#### Title page

The title page should contain (i) the title of the paper, (ii) the full names of the authors and (iii) the addresses of the institutions at which the work was carried out together with (iv) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript should be sent. The present address of any author, if different from that where the work was carried out, should be supplied in a footnote.

The title should be short, informative and contain the major key words. Do not use abbreviations in the title. A short running title (less than 40 characters) should also be provided.

#### Abstract and key words

All articles must have a brief abstract that states in 250 words the purpose, basic procedures, main findings and principal conclusions of the study. The abstract should not contain abbreviations or references.

Five key words, for the purposes of indexing, should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at <http://www.nlm.nih.gov/mesh/meshhome.html>.

#### Text

Authors should use the following sub-headings to divide the sections of their manuscript: Introduction, Methods, Results and Discussion.

**Acknowledgments**

The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors' industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Personal thanks and thanks to anonymous reviewers are not appropriate.

**Conflict of Interest (applies to all article types)**

At the time of submission, the Corresponding author must include a disclosure statement in the body of the manuscript. The statement will describe all of the authors' relationships with the companies that may have a financial interest in the information contained in the manuscript. This information should be provided under the heading titled 'Conflict of Interest' which should appear after the 'Acknowledgments' section and before the 'References' section. The absence of any interest to disclose must also be stated.

**References**

The Vancouver system of referencing should be used (examples are given below). In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited in tables or figure legends, number according to the first identification of the table or figure in the text.

In the reference list, cite the names of all authors when there are six or fewer; when seven or more, list the first three followed by *et al.* Do not use *ibid.* or *op cit.* Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2000, unpublished data). All citations mentioned in the text, tables or figures must be listed in the reference list.

Names of journals should be abbreviated in the style used in *Index Medicus*. Authors are responsible for the accuracy of the references.

**Standard journal article**

Vega KJ, Pina I, Krevsky B. Heart transplantation is associated with an increased risk for pancreaticobiliary disease. *Ann Intern Med* 1996; **124**: 980–983.

**Standard journal article using DOI articles published online in advance without volume, issue, or page number (More information about DOIs: <http://www.doi.org/faq.html>)**

2 Sonobe T, Kiyosawa N, Tsuchiya K, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. *Pediatr. Int.* Published online: 6 June 2007; doi: 10.1111/j.1442-200X.2007.02396.x

**Book**

2 Ringsven MK, Bond D. *Gerontology and Leadership Skills for Nurses*, 2nd edn. Albany, NY: Delmar Publishers, 1996.

**Chapter in a Book**

3 Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, eds. *Hypertension: Pathophysiology, Diagnosis, and Management*, 2nd edn. New York: Raven Press, 1995; 465–478.

**Tables**

Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables

consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and \*, \*\*, \*\*\* should be reserved for *P*-values. Statistical measures such as SD or SEM should be identified in the headings.

**Figures**

All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Line figures should be supplied as sharp, black and white graphs or diagrams, drawn professionally or with a computer graphics package; lettering should be included. Individual images forming a composite figure should be of equal contrast, to facilitate printing, and should be accurately squared. Images need to be cropped sufficiently to prevent the subject being recognized, or an eye bar used. Magnifications should be indicated using a scale bar on the illustration. Images should be supplied as high resolution (at least 300 d.p.i.) files, saved as .eps or .tif format. Digital images supplied only as low-resolution print-outs and/or files cannot be used.

**Figure legends**

Type figure legends on a separate page in the main document. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

**PROOFS**

It is essential that corresponding authors supply an email address to which correspondence can be emailed while their article is in production.

Notification of the URL from where to download a Portable Document Format (PDF) typeset page proof, associated forms and further instructions will be sent by email to the corresponding author. The purpose of the PDF proof is a final check of the layout, and of tables and figures. Alterations other than the *essential* correction of errors are unacceptable at PDF proof stage. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicated; otherwise, it may be signed off on by the Editor or held over to the next issue.

**OFFPRINTS**

A minimum of 50 offprints will be provided upon request, at the author's expense. These paper offprints may be ordered online. Please visit <http://offprint.cosprinters.com>, fill in the necessary details and ensure that you type information in all of the required fields. Free access to the final PDF offprint of your article will be available via author services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.

If you have queries about offprints, please email [offprint@cosprinters.com](mailto:offprint@cosprinters.com).

**PUBLICATION FEES**

From April 1, 2013, the publication charge will change to ¥20,000/US\$200 per printed page. (For articles submitted before April 1, 2013, the publication charge will remain US\$60 per printed page) A form requesting payment will be available for download with your PDF proof.

**COLOR FIGURE CHARGE**

Color figures will be published free of charge if judged relevant and of good quality.

**ONLINE GUIDELINES**

Visit the *The Journal of Dermatology* home page at <http://wileyonlinelibrary.com/journal/jde> for more information, and Wiley Publishing's web pages for submission guidelines and digital graphics standards at [http://authorservices.wiley.com/prep\\_illust.asp](http://authorservices.wiley.com/prep_illust.asp). *The Journal of Dermatology* is available online at Wiley Online Library. Visit [www.wileyonlinelibrary.com](http://www.wileyonlinelibrary.com) to search the articles and register for table of contents and email alerts.

Author Services enables authors to track their article, once it has been accepted, through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production so they do not need to contact the production editor to check on progress. Visit <http://authorservices.wiley.com/bauthor> for more details on online production tracking and for a wealth of resources, including FAQs and tips on article preparation, submission and more.

**EARLYVIEW**

*EarlyView* articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. *EarlyView* articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of *EarlyView* articles means that they do not yet have volume, issue or page numbers, so *EarlyView* articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found at: <http://www.doi.org/faq.html>

**Contact**

Professor Masutaka Furue  
Editor-in-Chief, *The Journal of Dermatology*  
1-4 Hongo-4-chome, Bunkyo-ku Tokyo  
113-0033 Japan  
Email: [gakkai@dermatol.or.jp](mailto:gakkai@dermatol.or.jp)  
Tel: +81 3 3811 5099; Fax: +81 3 3812 6790.